<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39358227</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1347-4715</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Environmental health and preventive medicine</Title><ISOAbbreviation>Environ Health Prev Med</ISOAbbreviation></Journal><ArticleTitle>Differential impact of SARS-CoV-2 infection during different outbreak periods on incident diabetes in Japan: a matched cohort study utilizing health insurance claims.</ArticleTitle><Pagination><StartPage>52</StartPage><MedlinePgn>52</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">52</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1265/ehpm.24-00191</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">An increased risk of diabetes after COVID-19 exposure has been reported in Caucasians during the early phase of the pandemic, but the effects across viral variants and in non-Caucasians have not been evaluated.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">To address this gap, survival analyses were performed for five outbreak periods. From an anonymized health insurance database REZULT for the employees and their dependents of large companies or government agencies in Japan, 5 matched cohorts were generated based on age, sex, area of residence (47 prefectures), and 7 ranges of medical bills (COVID-19 exposed:unexposed = 1:4). Observation of each matching group began on the same day. Incident diabetes type 1 (T1D) and type 2 (T2D) were defined as the first claim during the target period, including at least 1 year before the start of observation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">T1D accounted for 0.8% of incident diabetes after the first COVID-19 exposure, similar to the non-exposed cohort. Most T2D in the COVID-19 cohort was observed within a few weeks. After further adjustment for the number of days from the start of observation to hospitalization (a time-dependent variable), the hazard ratio for incident T2D ranged from 14.1 to 20.0, with 95% confidence intervals (95%CI) of 8.7 to 32.0, during the 2-month follow-ups from the original strain outbreak to the Delta variant outbreak (by September 2021), and decreased to 2.0, with a 95%CI of 1.6 to 2.5, during the Omicron outbreak (by March 2022). No association was found during the BA.4/5 outbreak (until September 2022). Males had a higher risk, and the trend toward higher risk in older age groups was inconsistent across the periods.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our large dataset, covering 2019-2023, reports for the first time the impact of COVID-19 on incident diabetes in non-Caucasians. The risk intensity and attributes of post-COVID-19 T2D were inconsistent across outbreak periods, suggesting diverse biological effects of different SARS-CoV-2 variants.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Matsumoto</LastName><ForeName>Akiko</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Social and Environmental Medicine, Saga University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kodera</LastName><ForeName>Sachiko</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center of Biomedical Physics and Information Technology, Nagoya Institute of Technology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuura</LastName><ForeName>Tatsuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center of Biomedical Physics and Information Technology, Nagoya Institute of Technology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takayama</LastName><ForeName>Yoko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center of Biomedical Physics and Information Technology, Nagoya Institute of Technology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Yuya</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Japan System Techniques Co., Ltd.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirata</LastName><ForeName>Akimasa</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8336-1140</Identifier><AffiliationInfo><Affiliation>Center of Biomedical Physics and Information Technology, Nagoya Institute of Technology.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Environ Health Prev Med</MedlineTA><NlmUniqueID>9609642</NlmUniqueID><ISSNLinking>1342-078X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003922" MajorTopicYN="N">Diabetes Mellitus, Type 1</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007348" MajorTopicYN="N">Insurance, Health</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Diabetes</Keyword><Keyword MajorTopicYN="N">Hazard ratio</Keyword><Keyword MajorTopicYN="N">Health insurance system</Keyword></KeywordList><CoiStatement>The authors have no competing interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>7</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39358227</ArticleId><ArticleId IdType="pmc">PMC11473386</ArticleId><ArticleId IdType="doi">10.1265/ehpm.24-00191</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mahase E. Covid-19: What do we know about “long covid”? BMJ. 2020;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">32665317</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett CE, Koyama AK, Alvarez P, Chow W, Lundeen EA, Perrine CG, et al.. Risk for Newly Diagnosed Diabetes &gt;30 Days After SARS-CoV-2 Infection Among Persons Aged &lt;18 Years - United States, March 1, 2020–June 28, 2021. MMWR Morb Mortal Wkly Rep. 2022;71:59–65. doi: 10.15585/mmwr.mm7102e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7102e2</ArticleId><ArticleId IdType="pmc">PMC8757617</ArticleId><ArticleId IdType="pubmed">35025851</ArticleId></ArticleIdList></Reference><Reference><Citation>Birabaharan M, Kaelber DC, Pettus JH, Smith DM. Risk of new-onset type 2 diabetes in 600 055 people after COVID-19: A cohort study. Diabetes Obes Metab. 2022;24:1176–9. doi: 10.1111/dom.14659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.14659</ArticleId><ArticleId IdType="pmc">PMC9035030</ArticleId><ArticleId IdType="pubmed">35112782</ArticleId></ArticleIdList></Reference><Reference><Citation>Qeadan F, Tingey B, Egbert J, Pezzolesi MG, Burge MR, Peterson KA, et al.. The associations between COVID-19 diagnosis, type 1 diabetes, and the risk of diabetic ketoacidosis: A nationwide cohort from the US using the Cerner Real-World Data. PLoS One. 2022;17:e0266809. doi: 10.1371/journal.pone.0266809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0266809</ArticleId><ArticleId IdType="pmc">PMC9017888</ArticleId><ArticleId IdType="pubmed">35439266</ArticleId></ArticleIdList></Reference><Reference><Citation>Kendall EK, Olaker VR, Kaelber DC, Xu R, Davis PB. Association of SARS-CoV-2 Infection With New-Onset Type 1 Diabetes Among Pediatric Patients From 2020 to 2021. JAMA Netw Open. 2022;5:e2233014. doi: 10.1001/jamanetworkopen.2022.33014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.33014</ArticleId><ArticleId IdType="pmc">PMC9508649</ArticleId><ArticleId IdType="pubmed">36149658</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, Khunti K, Nafilyan V, Maddox T, Humberstone B, Diamond I, et al.. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ. 2021;372:n693. doi: 10.1136/bmj.n693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n693</ArticleId><ArticleId IdType="pmc">PMC8010267</ArticleId><ArticleId IdType="pubmed">33789877</ArticleId></ArticleIdList></Reference><Reference><Citation>Wander PL, Lowy E, Beste LA, Tulloch-Palomino L, Korpak A, Peterson AC, et al.. The Incidence of Diabetes Among 2,777,768 Veterans With and Without Recent SARS-CoV-2 Infection. Diabetes Care. 2022;45:782–8. doi: 10.2337/dc21-1686.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc21-1686</ArticleId><ArticleId IdType="pmc">PMC9016731</ArticleId><ArticleId IdType="pubmed">35085391</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol. 2022;10:311–21. doi: 10.1016/S2213-8587(22)00044-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(22)00044-4</ArticleId><ArticleId IdType="pmc">PMC8937253</ArticleId><ArticleId IdType="pubmed">35325624</ArticleId></ArticleIdList></Reference><Reference><Citation>Takashima S, Tokiya M, Izui K, Miyamoto H, Matsumoto A. Asian flush is a potential protective factor against COVID-19: a web-based retrospective survey in Japan. Environ Health Prev Med. 2024;29:14. doi: 10.1265/ehpm.23-00361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1265/ehpm.23-00361</ArticleId><ArticleId IdType="pmc">PMC10937249</ArticleId><ArticleId IdType="pubmed">38462476</ArticleId></ArticleIdList></Reference><Reference><Citation>Namkoong H, Edahiro R, Takano T, Nishihara H, Shirai Y, Sonehara K, et al.. DOCK2 is involved in the host genetics and biology of severe COVID-19. Nature. 2022;609:754–60. doi: 10.1038/s41586-022-05163-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05163-5</ArticleId><ArticleId IdType="pmc">PMC9492544</ArticleId><ArticleId IdType="pubmed">35940203</ArticleId></ArticleIdList></Reference><Reference><Citation>Accili D. Can COVID-19 cause diabetes? Nat Metab. 2021;3:123–5. doi: 10.1038/s42255-020-00339-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42255-020-00339-7</ArticleId><ArticleId IdType="pmc">PMC8892570</ArticleId><ArticleId IdType="pubmed">33432203</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang X, Uhl S, Zhang T, Xue D, Li B, Vandana JJ, et al.. SARS-CoV-2 infection induces beta cell transdifferentiation. Cell Metab. 2021;33:1577–91 e7. doi: 10.1016/j.cmet.2021.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2021.05.015</ArticleId><ArticleId IdType="pmc">PMC8133495</ArticleId><ArticleId IdType="pubmed">34081913</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. Int J Infect Dis. 2022;114:252–60. doi: 10.1016/j.ijid.2021.11.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.11.009</ArticleId><ArticleId IdType="pmc">PMC8595975</ArticleId><ArticleId IdType="pubmed">34800687</ArticleId></ArticleIdList></Reference><Reference><Citation>Japanese Ministry of Health Labour and Welfare
https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/newpage_00045.html (2023).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>